Conavi Receives Late-Stage Innovation Grant from CMA
Conavi Medical is the recipient of the Late-Stage Innovation Grant from the Canadian Medical Association’s Joule Innovation Group. The Joule Innovation grant will give Conavi an opportunity to scale and solve medical challenges worldwide.
Japanese Sales Strategy of Novasight Hybrid™ System Announced
Conavi Medical is pleased to announce that Japan Lifeline has submitted an application for the regulatory approval of the Novasight HybridTM intravascular imaging system in Japan. In addition, Japan Lifeline will serve as the exclusive distributor of the Novasight Hybrid intravascular imaging system in Japan. Novasight Hybrid is the world’s first system to have been used clinically that is capable of providing both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) on a single imaging catheter. Earlier this year, the Novasight Hybrid system received FDA 510(k) clearance in the United States and was featured by Conavi Medical at the TCT 2018 Interventional Cardiology conference.
First Clinical Use of Novasight Hybrid™ System
Conavi Medical is pleased to announce the first clinical use of the Novasight HybridTM System, which enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT). IVUS or OCT are typically used by interventional cardiologists to image coronary anatomy during minimally invasive procedures, such as angiograms, angioplasty and stenting procedures. Drs. Tej Sheth and Natalia Pinilla Echeverri are co-investigators at Hamilton General Hospital where the procedures were performed under a Health Canada Investigational Testing Authorization.
MedTech Innovator Selects Conavi for 2018 Showcase
Conavi Medical is pleased to announce that we are among the 50 companies selected by MedTech Innovator to participate in the organization’s 2018 showcase. MedTech Innovator is a non-profit organization designed to identify and support innovative early-stage medical device companies. As part of our selection, the Conavi team will attend several MedTech Innovator conferences and events to pursue opportunities for mentorship and financial support from healthcare industry leaders.
Novasight Hybrid™ System Receives FDA 510(k) Clearance
Conavi has received 510(k) clearance from the US Food and Drug Administration (FDA) for our Novasight Hybrid™ System. The system enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT). IVUS or OCT are typically used by interventional cardiologists to image coronary anatomy during angioplasty and stenting procedures.
Conavi Enters into Distribution Agreement with China Grand Pharmaceutical and Healthcare
Conavi is pleased to announce that we have entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of our Foresight ICE System and Novasight Hybrid System in China, Hong Kong, Taiwan and Macau.